Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy

被引:24
|
作者
Nicosia, Luca [1 ]
Cuccia, Francesco [1 ]
Mazzola, Rosario [1 ]
Ricchetti, Francesco [1 ]
Figlia, Vanessa [1 ]
Giaj-Levra, Niccolo [1 ]
Rigo, Michele [1 ]
Tomasini, Davide [2 ]
Pasinetti, Nadia [3 ]
Corradini, Stefanie [4 ]
Ruggieri, Ruggero [1 ]
Alongi, Filippo [1 ,5 ]
机构
[1] IRCCS Sacro Cuore Don Calabria Hosp, Canc Care Ctr, Adv Radiat Oncol Dept, Via Don Sempreboni 5, I-37034 Verona, Negrar, Italy
[2] Brescia Univ, Radiat Oncol Dept, ASST Spedali Civili Brescia, Brescia, Italy
[3] ASL Valle Camon Sebino Esine, Dept Radiat Oncol, Osped Esine, Esine, Italy
[4] Ludwig Maximilians Univ Munchen, Univ Hosp, Radiat Oncol Dept, Munich, Germany
[5] Univ Brescia, Brescia, Italy
关键词
Metatases directed therapy; Stereotactic ablative radiotherapy; SABR; Gastrointestinal cancer; Polymetastatic disease; RADIATION-THERAPY SBRT; PROGNOSTIC-FACTORS; LIVER METASTASES; MUTATION; OUTCOMES; SURVIVAL;
D O I
10.1007/s00066-020-01627-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy (SABR) has been shown to increase survival rates in oligometastatic disease (OMD), but local control of colorectal metastases remains poor. We aimed to explore the natural course of oligometastatic colorectal cancer and to investigate how SBRT of lung metastases can delay the progression to polymetastatic disease (PMD). Methods 107 lung oligometastases in 38 patients were treated with SBRT at a single institution. The median number of treated lesions was 2 (range 1-5). Time to PMD (ttPMD) was defined as the time from SBRT to the occurrence of > 5 new metastases. Genetic biomarkers such as EGFR, KRAS, NRAS, BRAF, and microsatellite instability were investigated as predictive factors for response rates. Results Median follow-up was 28 months. At median follow-up, 7 patients were free from disease and 31 had progression: 18 patients had sequential oligometastatic disease (SOMD) and 13 polymetastatic progression. All SOMD cases received a second SBRT course. Median progression-free survival (PFS) was 7 months (range 4-9 months); median ttPMD was 25.8 months (range 12-39 months) with 1- and 2-year PFS rates of 62.5% and 53.4%, respectively. 1- and 2-year local PFS (LPFS) rates were 91.5% and 80%, respectively. At univariate analysis, BRAF wildtype correlated with better LPFS (p = 0.003), SOMD after primary SBRT was associated with longer cancer-specific survival (p = 0.031). Median overall survival (OS) was 39.5 months (range 26-64 months) and 2-year OS was 71.1%. Conclusion The present results support local ablative treatment of lung metastases using SBRT in oligometastatic colorectal cancer patients, as it can delay the transition to PMD. Patients who progressed as SOMD maintained a survival advantage compared to those who developed PMD.
引用
收藏
页码:813 / 820
页数:8
相关论文
共 50 条
  • [31] Stereotactic ablative body radiotherapy (SAbR) for oligometastatic cancer
    Desai, Neil B.
    Laine, Aaron M.
    Timmerman, Robert D.
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2017, 90 (1070):
  • [32] Clinical Results of Stereotactic Body Radiotherapy for Oligometastatic Lung Tumors
    Shioyama, Y.
    Nomoto, S.
    Ohga, S.
    Nonoshita, T.
    Ohnishi, K.
    Terashima, K.
    Nakamura, K.
    Hirata, H.
    Honda, H.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S456 - S457
  • [33] Patients With Oligometastatic Disease Limited to the Chest Are Optimal Candidates for Lung Stereotactic Body Radiotherapy
    Fega, Rebecca
    Goyal, Uma
    Ross, Helen
    Jaroszewski, Dawn
    Paripati, Harshita
    Heidi, Kosiorek
    Daniels, Thomas
    Rule, William
    Schild, Steven
    Vora, Sujay
    Ashman, Jonathan
    [J]. CHEST, 2016, 150 (04) : 978A - 978A
  • [34] An Institution Review of Outcomes of Lung Stereotactic Body Radiotherapy in Various Oligometastatic Disease States
    Chia, B.
    Ng, W. L.
    Yap, S. P.
    Chua, K.
    Yip, C.
    Thiagarajan, A.
    Siow, T. R.
    Fong, K. W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S942 - S942
  • [35] Efficacy and Toxicity of Robotic Stereotactic Body Radiotherapy of Lung Metastases in Patients With Oligometastatic Disease
    Rosenbrock, Johannes
    Lieser, Annabell
    Ostermann-Myrau, Julia
    Judge, Michael
    Linde, Philipp
    Claus, Karina
    Marnitz, Simone
    Kocher, Martin
    Baues, Christian
    Celik, Eren
    [J]. ANTICANCER RESEARCH, 2023, 43 (09) : 4125 - 4131
  • [36] Stereotactic body radiotherapy in patients with adrenal gland metastases of oligometastatic and oliogoprogressive lung cancer
    Rzazade, Rashad
    Pham, Ngoc T.
    Turna, Menekse
    Canoglu, Mehmet Dogu
    Kucukmorkoc, Esra
    Berberoglu, Kezban
    Caglar, Hale Basak
    [J]. JOURNAL OF RADIOSURGERY AND SBRT, 2023, 8 (04): : 275 - 282
  • [37] Stereotactic Body Radiotherapy for Oligometastatic Non-small Cell Lung Cancer Patients
    Mascitillo, S.
    Bonucci, I.
    Menichelli, C.
    Masi, L.
    Doro, R.
    Casamassima, F.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S539 - S540
  • [38] Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy
    Franzese, Ciro
    Comito, Tiziana
    Toska, Eno
    Tozzi, Angelo
    Clerici, Elena
    De Rose, Fiorenza
    Franceschini, Davide
    Navarria, Pierina
    Reggiori, Giacomo
    Tomatis, Stefano
    Scorsetti, Marta
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 133 : 220 - 226
  • [39] Oligometastatic Non Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy (SBRT), a Single Institution Experience
    Franceschini, D.
    De Rose, F.
    Radicioni, G.
    Toska, E.
    Faraci, L.
    Carta, G.
    Scorsetti, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S939 - S939
  • [40] Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review
    Kobiela, J.
    Spychalski, P.
    Marvaso, G.
    Ciardo, D.
    Dell'Acqua, V.
    Kraja, F.
    Blazynska-Spychalska, A.
    Lachinski, A. J.
    Surgo, A.
    Glynne-Jones, R.
    Jereczek-Fossa, B. A.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 129 : 91 - 101